Fulvestrant

Fulvestrant, also known as ICI 182,780, is a drug treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor.^[1] It is administered as a once-monthly injection.

Fulvestrant is marketed by AstraZeneca with the brand name Faslodex.

Clinical uses

Fulvestrant is a Selective Estrogen Receptor Down-Regulator (SERD). Fulvestrant is indicated for the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy. The dosing schedule for fulvestrant remains under investigation in an attempt to optimize its effectiveness.^[2]

External links

• Faslodex product website
• Faslodex prescribing information

References

1. ^ S. Kansra, S. Yamagata, L. Sneade, L. Foster & N. Ben-Jonathan (2005). "Differential effects of estrogen receptor antagonists on pituitary lactotroph proliferation and prolactin release". Mol Cell Endocrinol 239 (1-2): 27–36. doi:10.1016/j.mce.2005.04.008. PMID 15950373. 
2. ^ Angela Mae Obermiller, PharmD; and Mehmet Sitki Copur, MD (2011). "The Longstanding Quest for a Better Endocrine Therapy Continues High-Dose Fulvestrant: Have We Found Its Effective Dose, Combination, Setting, or Sequence?". Contemporary Oncology 3 (1). http://www.onclive.com/publications/contemporary-oncology/2011/spring-2011/the-longstanding-quest-for-a-better-endocrine-therapy-continues-high-dose-fulvestrant/.